
Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

ICD-10 C53-C55: Uterine cancer

Survival



GERMANY BAVARIA MUNICH

Munich Cancer Registry Cancer Registry Bavaria - Upper Bavaria Regional Center at Klinikum Grosshadern/IBE Marchioninistr. 15 Munich, 81377 Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/surv/sC5355E-ICD-10-C53-C55-Uterine-cancer-survival.pdf

Index of figures and tables

Fig./Tb	ol.	Page
1a	Relative survival by period of diagnosis (chart)	3
1b	Survival by period of diagnosis (table)	3
2a	Survival of total cohort (chart)	4
2b	Survival of total cohort (table)	4
3a	Observed survival by age category (chart)	5
3b	Relative survival by age category (chart)	5
3c	Survival by age category (table)	6
4a	Relative survival by ICD-10 classification (chart)	7
4b	Survival by ICD-10 classification (table)	7
4c	Conditional survival by extent of disease (chart)	8
4d	Conditional survival by extent of disease (table)	8
4c	Relative survival by extent of disease (chart)	9
4d	Survival by extent of disease (table)	9
5a	Time to first progression (chart)	10
5b	Time to first progression (table)	10
5c	Observed post-progression survival (chart)	12
5d	Observed post-progression survival (table)	12
5e	Observed post-progression survival by period of progression (chart)	13
5f	Observed post-progression survival by period of progression (table)	13




Figure 1a. Relative survival of patients with uterine cancer by period of diagnosis. Included in the evaluation are 17,557 cases diagnosed between 1988 and 2020.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2018, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Period of diagnosis								
	1988-	1997	1998-2006		2007-	2015	201	6+
	n=3,161		n=4,816		n=6,394		n=3,186	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	90.5	92.5	90.1	91.9	90.5	92.1	90.9	92.3
2	82.2	85.8	83.1	86.3	83.3	86.1	84.7	87.3
3	76.4	81.4	78.3	82.8	78.3	82.3	79.8	83.4
4	72.1	78.4	74.8	80.5	74.5	79.6	76.6	81.2
5	69.1	76.8	71.8	78.6	71.5	77.6	74.3	79.9
6	66.6	75.6	68.8	76.7	68.7	75.9		
7	63.9	74.0	66.6	75.6	66.4	74.6		
8	61.8	73.1	64.6	74.7	64.5	73.7		
9	59.4	71.8	62.8	74.0	62.8	73.1		
10	57.8	71.3	61.0	73.2	61.0	72.3		
11	55.2	69.6	59.1	72.5	59.2	71.6		
12	53.4	68.8	57.3	71.8	57.3	70.7		
13	51.8	68.2	55.1	70.5	55.8	70.3		
14	49.8	67.0	52.7	69.0	51.9	66.9		
15	47.8	65.8	51.0	68.3				
Median	13.8		15.5		14.3			

Table 1b. Observed (obs.) and relative (rel.) survival of patients with uterine cancer by period of diagnosis for period 1988-2020 (N=17,557).




Figure 2a. Observed, expected and relative survival of the total cohort with uterine cancer. Included in the evaluation are 14,396 cases diagnosed between 1998 and 2020.

	Group			
	-	All patients		
	n=14			
Years				
-	obs. %			
0	100.0	100.0		
1	90.5	92.1		
2	83.5	86.4		
3	78.6	82.7		
4	75.0	80.2		
5	72.0	78.3		
6	69.1	76.5		
7	66.8	75.3		
8	64.9	74.4		
9	63.1	73.7		
10	61.3	73.0		
11	59.5	72.2		
12	57.6	71.4		
13	55.6	70.4		
14	53.0	68.7		
15	51.3	68.0		
Median	15.7			

Table 2b. Observed (obs.) and relative (rel.) survival of the total cohort with uterine cancer for period 1998-2020 (N=14,396).




Figure 3a. Observed survival of patients with uterine cancer by age category. Included in the evaluation are 14,396 cases diagnosed between 1998 and 2020.




Figure 3b. Relative survival of patients with uterine cancer by age category. Included in the evaluation are 14,396 cases diagnosed between 1998 and 2020.

				Age	categ	ory				
	0-49	yrs	50-5	9 yrs	60-69 yrs		70-79 yrs		80+	yrs
	n=2,	987	n=2,	,833	n=3,	675	n=3,	257	n=1,	644
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.8	95.9	94.1	94.5	92.8	93.5	88.5	90.5	73.4	80.4
2	91.9	92.1	88.3	88.9	87.4	88.8	79.8	83.5	59.3	71.3
3	88.5	88.8	85.2	86.1	83.2	85.5	73.6	79.2	49.8	66.1
4	86.4	86.8	82.6	84.0	80.1	83.0	68.8	76.1	43.5	64.2
5	85.0	85.5	80.6	82.3	77.3	81.1	65.2	74.6	36.5	60.6
6	83.7	84.3	79.2	81.3	75.0	79.7	61.0	72.4	30.5	57.4
7	82.8	83.5	78.0	80.5	73.0	78.6	57.6	71.2	25.8	55.8
8	82.3	83.2	77.0	80.0	71.3	77.9	54.0	69.9	22.5	56.4
9	81.8	82.8	76.3	79.9	69.8	77.6	50.7	69.0	19.4	57.2
10	81.5	82.7	75.0	79.1	68.3	77.3	48.0	69.3	15.2	53.9
11	80.9	82.3	74.4	79.1	66.4	76.7	44.4	68.3	13.3	57.5
12	80.6	82.1	73.6	78.9	64.7	76.4	40.6	67.3	10.7	58.0
13	79.9	81.8	72.6	78.6	62.9	76.0	36.6	65.8	8.3	56.9
14	78.9	81.0	70.8	77.5	59.7	74.3	32.4	63.9	6.9	61.6
15	78.4	80.7	69.8	77.3	58.0	74.4	28.9	63.0	5.3	64.2
Median					18.4		9.4		2.9	

Table 3c. Observed (obs.) and relative (rel.) survival of patients with uterine cancer by age category for period 1998-2020 (N=14,396).




Figure 4a. Relative survival of patients with uterine cancer by ICD-10 classification. Included in the evaluation are 14,396 cases diagnosed between 1998 and 2020.

	IC	CD-10	classification					
	C53 C	Cervix	C54 C	orpus	C55 Uterus			
	ute	eri	ute	eri	unspec.			
	n=4,453		n=9,842		n=101			
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %		
0	100.0	100.0	100.0	100.0	100.0	100.0		
1	88.4	89.3	91.6	93.6	68.2	69.8		
2	80.2	81.5	85.2	88.9	61.4	63.9		
3	74.8	76.5	80.4	85.7	60.2	63.6		
4	71.6	73.7	76.7	83.4	56.6	61.1		
5	68.7	71.1	73.7	81.8	49.4	54.5		
6	66.8	69.6	70.4	80.0	44.3	49.9		
7	65.3	68.4	67.8	78.8	40.5	46.3		
8	63.9	67.4	65.6	78.0	40.5	46.3		
9	63.0	66.8	63.4	77.3	40.5	46.4		
10	62.1	66.3	61.2	76.5	40.5	46.4		
Median			14.6		4.9	\sim		

Table 4b. Observed (obs.) and relative (rel.) survival of patients with uterine cancer by ICD-10 classification for period 1998-2020 (N=14,396).




Figure 4c. Conditional relative 5-year survival of patients with uterine cancer by extent of disease. For 13,702 of 14,396 cases diagnosed between 1998 and 2020 valid data could be obtained for this item. For a total of 13,639 cases an evaluable classification was established. The grey line represents the subgroup of 757 patients with missing values regarding extent of disease (5.3 % of 14,396 patients, the percent values of all other categories are related to n=13,639).

Extent of disease								
	Loc	al	Regional		Distant		NA/NOS	
		Cond. surv. %		Cond. surv. %		Cond. surv. %		Cond. surv. %
Years	n	5 yrs	n	5 yrs	n	5 yrs	n	5 yrs
0	11,142	88.2	1,426	57.2	1,071	19.6	757	55.1
1	10,169	89.4	1,170	62.9	596	30.8	522	69.3
2	9,259	91.3	931	71.0	356	45.9	431	77.2
3	8,376	93.1	781	76.1	238	60.7	362	84.7
4	7,561	94.4	660	83.0	173	72.9	313	87.0
5	6,805	95.7	571	87.5	130	79.3	288	86.8
6	6,158	96.8	502	90.8	103	85.5	256	90.2
7	5,540	97.3	430	94.4	87	87.6	242	89.8
8	4,979	97.1	367	97.2	73	86.7	225	90.2
9	4,442	96.0	327	95.1			205	90.3
10	3,929	96.2	297	94.4			184	92.6

Table 4d. Conditional relative 5-year survival of patients with uterine cancer by extent of disease for period 1998-2020 (N=13,639).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 4a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 93.1% (n=8,376).




Figure 4c. Relative survival of patients with uterine cancer by extent of disease. For 13,702 of 14,396 cases diagnosed between 1998 and 2020 valid data could be obtained for this item. For a total of 13,639 cases an evaluable classification was established. The grey line represents the subgroup of 757 patients with missing values regarding extent of disease (5.3 % of 14,396 patients, the percent values of all other categories are related to n=13,639).

	Extent of disease							
	Lo	cal	Regi	Regional Dis		tant	NA/NOS	
	n=11	,142	n=1,	426	n=1,	,071	n=7	'57
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.5	97.1	85.9	86.9	57.1	58.1	73.1	75.7
2	90.9	94.1	71.8	73.5	36.5	37.5	63.2	67.0
3	87.1	91.7	63.6	65.7	26.6	27.6	55.7	60.2
4	84.0	89.9	57.6	60.1	21.5	22.6	51.6	56.7
5	80.9	88.2	54.2	57.2	18.4	19.6	49.4	55.1
6	78.0	86.6	51.3	54.6	16.5	17.8	46.2	52.2
7	75.6	85.4	48.3	52.0	15.6	17.2	44.9	51.3
8	73.5	84.7	45.9	49.9	15.0	16.7	43.6	50.5
9	71.5	84.0	45.2	49.7	14.6	16.4	41.6	48.7
10	69.4	83.2	44.8	49.8	13.6	15.4	39.9	47.3
Median	19.2		6.4		1.3		4.4	

Table 4d. Observed (obs.) and relative (rel.) survival of patients with uterine cancer by extent of disease for period 1998-2020 (N=13,639).




Figure 5a. Time to first progression of 14,346 patients with uterine cancer diagnosed between 1998 and 2020 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

			Type of	f progressior	1		
	Any type (CI)	Any type (1- KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	Distant metastasis (CI)
N Events compet.	3,111 1,890	13,298 3,111	14,346 1,205 4,357	14,346 1,205	14,346 370 4,932	14,346 370	13,298 1,992 2,651
Years	%	%	%	%	%	%	%
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	10.3	10.4	2.8	3.0	0.8	0.8	5.2
2	16.3	16.6	5.6	6.1	1.6	1.7	9.4
3	19.4	19.8	6.9	7.7	2.0	2.3	11.9
4	21.2	21.7	7.7	8.6	2.3	2.6	13.4
5	22.4	23.0	8.1	9.3	2.5	2.9	14.4
6	23.4	24.1	8.5	9.7	2.6	3.0	15.1
7	24.1	24.8	8.8	10.1	2.6	3.1	15.6
8	24.6	25.4	8.9	10.3	2.7	3.2	16.0
9	25.0	25.9	9.1	10.6	2.8	3.3	16.3
10	25.2	26.1	9.2	10.7	2.9	3.4	16.4
11	25.4	26.4	9.2	10.8	2.9	3.5	16.6
12	25.8	26.9	9.3	10.9	2.9	3.6	16.8
13	26.0	27.1	9.4	11.0	2.9	3.6	17.0
14	26.3	27.6	9.5	11.2	3.0	3.7	17.1
15	26.6	28.1	9.6	11.4	3.0	3.7	17.2

Type of progression									
	Distant								
cont'd	metast. (1-	NOS (CI)	NOS (1-KM)						
	KM)								
N	13,298	14,346	14,346						
Events	1,992	849	849						
compet.		4,494							
Years	%	%	%						
0	0.0	0.0	0.0						
1	5.4	3.7	3.8						
2	9.8	4.8	5.0						
3	12.4	5.2	5.5						
4	14.1	5.5	5.9						
5	15.3	5.6	6.1						
6	16.1	5.8	6.3						
7	16.7	6.0	6.6						
8	17.2	6.0	6.7						
9	17.5	6.2	6.8						
10	17.7	6.2	6.9						
11	18.0	6.3	7.0						
12	18.3	6.3	7.1						
13	18.5	6.4	7.2						
14	18.7	6.6	7.5						
15	18.8	6.7	7.7						

Table 5b. Time to first progression of patients with uterine cancer for period 1998-2020 (N=14,346), also showing the total of progression events (Events) and of deaths as competing risk (compet.).




Figure 5c. Observed post-progression survival of 3,363 patients with uterine cancer diagnosed between 1998 and 2020. These 3,363 patients with documented progression events during their course of disease represent 23.4 % of the totally 14,346 evaluated cases (incl. M1, n=1,048, 7.3 %). Patients with cancer relapse documented via death certificates only were excluded (n=815, 5.7 %). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "Any type" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potientially considered in more than one subgroup.

Type of progression							
Any type	Local relapse	Lymph node	Distant metastasis	NOS			
n=3,363	n=1,211	n=372	n=2,500	n=426			
%	%	%	%	%			
100.0	100.0	100.0	100.0	100.0			
58.8	61.5	59.9	52.4	63.1			
40.2	43.4	36.8	33.1	46.2			
31.2	34.8	29.4	24.0	38.9			
26.2	29.9	25.0	19.2	34.6			
23.0	26.7	22.0	16.4	30.2			
20.9	24.6	21.0	14.7	27.7			
19.5	23.1	19.2	14.0	25.4			
18.4	21.7	17.8	13.1	24.4			
17.8	20.5	17.8	12.8	24.4			
16.9	19.5		12.2	22.7			
	n=3,363 % 100.0 58.8 40.2 31.2 26.2 23.0 20.9 19.5 18.4 17.8	Any type Local relapse n=3,363 n=1,211 % % 100.0 100.0 58.8 61.5 40.2 43.4 31.2 34.8 26.2 29.9 23.0 26.7 20.9 24.6 19.5 23.1 18.4 21.7 17.8 20.5	Any typeLocal relapseLymph noden=3,363n=1,211 %n=372 %100.0100.058.861.559.940.240.243.431.234.826.229.923.026.720.924.621.019.523.118.421.717.820.517.8	Any typeLocal relapseLymph nodeDistant metastasisn=3,363n=1,211 %n=372 %n=2,500 %100.0100.0100.0100.058.861.559.952.440.243.436.833.131.234.829.424.026.229.925.019.223.026.722.016.420.924.621.014.719.523.119.214.018.421.717.813.117.820.517.812.8			

Table 5d. Observed post-progression survival of patients with uterine cancer for period 1998-2020 (N=3,363).




Figure 5e. Observed post-progression (distant metastasis) survival of 2,846 patients with uterine cancer diagnosed between 1988 and 2020 by period of progression.

	P	eriod of prog	ression	
	1988-1997	1998-2006	2007-2015	2016+
	n=239	n=617	n=1,246	n=744
Years	%	%	%	%
0	100.0	100.0	100.0	100.0
1	30.9	41.4	54.1	59.1
2	16.9	24.2	33.7	40.8
3	11.6	17.7	24.2	30.6
4	9.3	14.3	19.5	24.4
5	8.9	12.0	16.6	
6		10.8	14.5	
7		10.1	13.8	
8		9.6	12.9	
9		9.4	12.5	
10		8.9	11.9	

Table 5f. Observed post-progression (distant metastasis) survival of patients with uterine cancer for period 1988-2020 by period of progression (N=2,846).



Shortcuts

MCR	Munich Cancer Registry, Germany						
NCI	National Cancer Institute, L						
SEER	Surveillance, Epidemiology	, and End Results, USA					
UICC	Union for International Can	cer Control, Geneva					
DCO	Death certificate only	Death certificate provides the only notification to the registry.					
NA	Not available						
NOS	Not otherwise specified						
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause					
RS	Relative survival	Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival					
AS	Assembled survival	Assembled chart of observed, expected, relative survival					
CS	Conditional survival	Survival probability under the condition of surviving a given period of time					
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression					
	1-КМ	1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)					
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)					
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause					

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C53-C55: Uterine cancer [Internet]. 2022 [updated 2022 Apr 15; cited 2022 Jun 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sC5355E-ICD-10-C53-C55-Uterine-cancer-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.